Kantify

Kantify is a Brussels-based Frontier Lab using AI to discover new medicines against previously undruggable targets. The company was built on the conviction that patients with intractable targets deserve access to molecules that conventional methods cannot reach. Kantify's platform, Sapian, is an AI-native, orthogonal approach to drug discovery. It integrates target identification with non-structure-based small molecule design—pioneering a method that requires no experimental structural data and operates independently of traditional screening infrastructures. Sapian screens billions of compounds in silico, combining advanced multi-parameter optimization with proteome-wide selectivity.